Condition
Healthy controls (investigating preclinical Alzheimer's Disease)
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Flortaucipir 18f
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Recruiting2
Clinical Trials (2)
Research Network
Common Treatments
- Flortaucipir 18f1
- Flutemetamol 18f1